# Antido Therapeutics (Australia) Pty Ltd: Phase 1 study in Advanced Solid Tumor (26 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Antido Therapeutics (Australia) Pty Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety and Tolerability of AT-0174 in Adults With Advanced Solid Tumors |
| NCT ID | NCT07885267 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Advanced Solid Tumor |
| Intervention types | drug |
| Target enrollment | 26 |
| Site countries | Australia |
| Posted | 2026-10-21 |
| Planned start | 2023-11-15 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07885267). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.